Costin Antonescu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Province of ontarioCyclica polypharmNaheed kurjiJennifer saccoCostin antonescuBo wangEngineering research council of canadaRyerson university is canadaNatural sciencesCanadian institute for advanced researchDepartment of chemistryRyerson universityVector instituteStimulus programCanadian instituteAdvanced research

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Province of ontarioCyclica polypharmNaheed kurjiCostin antonescuBo wangEngineering research council of canadaRyerson university is canadaNatural sciencesCanadian institute for advanced researchDepartment of chemistryRyerson universityVector instituteStimulus programCanadian instituteAdvanced researchEngineering research council

Cyclica : Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

New findings accelerated by Cyclica’s drug discovery platform suggest lung cancer drug capmatinib demonstrates robust antiviral effects in experimental COVID-19 models. .

Cyclica polypharmNaheed kurjiCostin antonescuBo wangEngineering research council of canadaRyerson university is canadaNatural sciencesCanadian institute for advanced researchDepartment of chemistryRyerson universityStimulus programVector instituteCanadian instituteAdvanced researchEngineering research councilNon small cell

Cyclica, academics team up to investigate COVID-19 treatment

The drug-discovery firm has partnered with several academic institutions to explore a Novartis lung-cancer treatment’s potential in treating COVID-19. Cyclica, a company specializing in data-driven drug discovery, has determined that the lung-cancer drug capmatinib shows evidence of attenuating the impact of coronavirus. The firm made the discovery via collaboration with Ryerson, the Vector Institute, and other Canadian institutions; funding came through COVID-19 grants from the Canadian Institute for Advanced Research (CIFAR) and Natural Sciences and Engineering Research Council of Canada (NSERC) Alliance COVID-19 grants, with funding support from FedDev Ontario. Capmatinib is an FDA-approved MET inhibitor, marketed by Novartis under the name Tabrecta; the treatment is used in clinical applications to treat patients with non-small-cell lung cancer. According to the researchers, testing capmatinib in a collection of experiments evaluating viral infect

Cyclica polypharmCostin antonescuBo wangDepartment of chemistryRyerson universityEngineering research council of canadaNatural sciencesCanadian institute for advanced researchVector instituteCanadian instituteAdvanced researchEngineering research councilபோ வாங்துறை ஆஃப் வேதியியல்ரைர்சன் பல்கலைக்கழகம்பொறியியல் ஆராய்ச்சி சபை ஆஃப் கனடா